Latest Administration News

Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.

Sequoia Financial Group reports a 15% rise in EBITDA year-to-date November 2025 despite legacy claim settlements and expected impairments, while its APAC expansion gains momentum.

Lake Resources has disclosed an inadvertent breach of ASX Listing Rule 7.1 related to the timing of share issuance under an agreement with Acuity Capital. The company is taking steps to strengthen governance and prevent future errors.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

AusQuest and South32 have extended their Strategic Alliance Agreement for two more years, securing continued funding and collaboration on Australian copper and zinc projects. South32 will fund exploration to advance projects to drill-ready status and can earn up to 80% interest through staged investments.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

Lycopodium Limited has addressed ASX concerns over delayed director interest disclosures, attributing the lapse to an administrative oversight while reaffirming its compliance policies.

Alicanto Minerals has acknowledged a late filing of a director’s interest notice, attributing it to an administrative oversight. The ASX has queried the delay, prompting the company to review its disclosure procedures.

Amplitude Energy has addressed an ASX query regarding the delayed filing of a director’s interest change, attributing it to an administrative oversight while affirming its compliance framework.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

Antares Metals has completed the first tranche of a $2 million capital raise, issuing over 128 million shares to support new project acquisitions and ongoing exploration activities.

Elixir Energy Limited has responded to ASX concerns over a delayed director interest disclosure, attributing the lapse to administrative changes and reaffirming its compliance protocols.